Peter G. Tombros
Chairman of the Board
Professor and Executive in Residence in the Eberly College of Science B.S. / M.B.A. Program at Pennsylvania State University
Michael W. Bonney
President and Chief Executive Officer, Cubist Pharmaceuticals, Inc.
Colin Broom, M.D.
Vice President and Chief Scientific Officer, ViroPharma Incorporated
James G. Groninger
Chief Executive Officer, LBS Technologies and President, The Bay South Company
Donald E. Kuhla, Ph.D.
Director, Albany Molecular Research, Inc.
Francois Nader, M.D.
President and Chief Executive Officer, NPS Pharmaceuticals, Inc.
Rachel R. Selisker, CPA
President, Seamark Advisors LLC
Peter G. Tombros
Chairman of the Board
Professor and Executive in Residence in the Eberly College of Science B.S. / M.B.A. Program at Pennsylvania State University
Mr. Tombros has served as a director since 1998 and in January 2008 was appointed chair of the board. Since 2005, Mr. Tombros has served as professor and executive in residence in the Eberly College of Science BS/MBA Program at Pennsylvania State University. Prior to that he was chair of the board and chief executive officer of VivoQuest, a private biopharmaceutical company. From 1994 until June of 2001, Mr. Tombros served as president, chief executive officer and director of Enzon Pharmaceuticals, a publicly held biopharmaceutical company. Prior to joining Enzon, Mr. Tombros spent 25 years with Pfizer Inc., a global healthcare company, in a variety of senior management positions including vice president of marketing, senior vice president and general manager of the Roerig Pharmaceuticals Division, executive vice president of Pfizer Pharmaceuticals Division, director of Pfizer Pharmaceuticals Division, vice president of corporate strategic planning, and vice president, corporate officer, Pfizer Inc. Mr. Tombros serves as a director and non-executive chair of the Board of PharmaNet Development Group, Inc. Mr. Tombros also serves on the board of directors of Cambrex and Protalex, Inc. Mr. Tombros received B.S. and M.S. degrees from Pennsylvania State University and an M.B.A. degree from the University of Pennsylvania Wharton Graduate School of Business.
Michael W. Bonney
President and CEO, Cubist Pharmaceuticals, Inc.
Mr. Bonney has served as a director since January 2005. Mr. Bonney has served since June 2003 as the president and chief executive officer and as a member of the Board of Directors of Cubist Pharmaceuticals, Inc., a public biopharmaceutical company. From January 2002 to June 2003, he served as its president and chief operating officer. From 1995 to 2001, he held various positions at Biogen, Inc., a public biopharmaceutical company, including vice president, sales and marketing from 1999 to 2001. Prior to that, Mr. Bonney held various positions in sales, marketing and strategic planning at Zeneca Pharmaceuticals, ending his eleven-year career there serving as National Business Director. Mr. Bonney has a B.A. in Economics from Bates College. Mr. Bonney is a trustee of Beth Israel Deaconess Medical Center and Bates College, and a member of the Board of Directors of BIO (Biotechnology Industry Organization).
Colin Broom, M.D.
Vice President and Chief Scientific Officer, ViroPharma Incorporated
Dr. Broom has been a director since July 2009. Since May 2004, he has served as vice president and chief scientific officer of ViroPharma Incorporated, a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital setting. At ViroPharma, Dr. Broom is responsible for the leadership of all research and development and medical affairs activities. Prior to ViroPharma, Dr. Broom served as vice president of clinical development and medical affairs, Europe, for Amgen. Previously, he was vice president of clinical development for Hoechst Marion Roussel (now sanofi-aventis) and for 14 years worked for Glaxo and then SmithKline Beecham (now GlaxoSmithKline) in a range of leadership positions of increasing responsibility, including head of global oncology and vice president of CNS/GI. Dr. Broom holds a bachelor of science degree in pharmacology from University College, London and a bachelor of medicine and bachelor of surgery degree from St. George’s Hospital Medical School, London. He is a Member of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the UK Colleges of Physicians.
James G. Groninger
Chief Executive Officer, LBS Technologies and President, The Bay South Company
Mr. Groninger has served as a director since 1988. In February 2002, Mr. Groninger was appointed chief executive officer of LBS Technologies, Inc., a private biotechnology company focusing on RNA amplification and cellular therapy. Mr. Groninger founded in January 1995 and is president of The Bay South Company, a Richmond, Virginia-based provider of financial advisory and investment banking services. From 1988 through 1994, he served as a managing director, investment banking division, of PaineWebber Incorporated. Mr. Groninger is a member of the board of directors of Cygne Designs, Inc., a publicly held company and Layton BioScience, Inc., LBS Technologies, Inc., and Expression Pathology, Inc., private biotechnology companies. Mr. Groninger received a B.S. from Yale University and an M.B.A. degree from Harvard Business School, and has been certified with CPA and CFA designations.
Donald E. Kuhla, Ph.D.
Director, Albany Molecular Research, Inc.
Dr. Kuhla has served as a director since 1991. From 1998 through January 2004, Dr. Kuhla was president and chief operating officer of Albany Molecular Research, Inc., a chemical contract research organization, which Dr. Kuhla continues to serve as a director. From 1994 through 1998 Dr. Kuhla was vice president of Plexus Ventures, Inc., a business consulting firm. From 1990 to 1994, Dr. Kuhla held senior management positions with two venture capital-backed, biotechnology startup companies. His early career was spent in research and development and operations management positions with Pfizer Inc. and Rorer Group, Inc., his last position at Rorer being senior vice president of operations. Dr. Kuhla is a director of Synthetech Inc., a pharmaceutical fine chemical company. Dr. Kuhla received a Ph.D. degree in Organic Chemistry from Ohio State University.
Francois Nader, M.D.
President and Chief Executive Officer, NPS Pharmaceuticals, Inc.
Francois Nader has been president and chief executive officer of NPS since March 2008. Dr. Nader joined NPS in June 2006 and served as executive vice president and chief operating officer until March 2008. In that capacity, he was responsible for managing the company's worldwide research and development, commercial operations, manufacturing and regulatory affairs. Before joining NPS, Dr. Nader was a venture partner at Care Capital, LLC and chief medical officer of its clinical development capital unit from July 2005, to June 2006. From 2000 to July 2005, he served as senior vice president, integrated healthcare markets and senior vice-president, North America medical and regulatory affairs with Aventis Pharmaceuticals. He also held similar positions at Hoechst Marion Roussel and served as head of global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader received a French State Doctorate in Medicine from St. Joseph University and a Physician Executive M.B.A. from the University of Tennessee.
Rachel R. Selisker, CPA
President, Seamark Advisors LLC
Ms. Selisker has served as a director since January 2005. Ms. Selisker is president of Seamark Advisors LLC and has provided financial consulting and appraisal services in the healthcare sector since June 2007. She served from March 2006 to June 2007 as chief financial officer of AAIPharma Inc., a privately held contract research organization. From January 2001 to March 2006 she served as a managing director in the Raleigh, North Carolina office of Thompson Clive & Partners Inc., a venture capital firm based in London, where she focused on the life sciences sector. She served from July 1987 to February 2000 as the chief financial officer, and from February 2000 to January 2001 as senior vice president, global shared services, of Quintiles Transnational Corp., a publicly held global contract research organization. Ms. Selisker also served as director of Quintiles Transnational Corp. from November 1995 to February 2000. Ms. Selisker was a supervisor and staff accountant with the national accounting firm of Oppenheim, Appel, Dixon & Co. in Raleigh, North Carolina, from 1981 to 1987. She is a certified public accountant with extensive public accounting experience from 1976, when she graduated with her accounting degree from Wake Technical College in Raleigh, North Carolina until 1987, when she joined Quintiles. She also has served as a director of Labopharm, Inc. since November 2008.